Here's Why Bausch Health Stock Gained 14.7% in a Week
BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.
Opinion
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, writes Ken Squire of 13D Monitor.
Bausch + Lomb’s stock soars 14% on report company is considering selling itself
The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.
Bausch Health Taps Jefferies to Refinance Debt, Aid Spinoff
Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, according to people with knowledge of the situation.
Bausch + Lomb reportedly exploring sale to handle Bausch Health spinoff
Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.
Bausch + Lomb Soars on Report That It’s Exploring a Sale
Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to disentangle from its debt-laden parent company.
Bausch + Lomb Stock Jumps Amid Reports Of A Sale
Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.
Bausch & Lomb gains after report of PE interest in takeover
Bausch & Lomb (NYSE:BLCO) rose 1.8% in premarket trading after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International,
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
The Financial Times6d
Private equity suitors line up for Bausch + Lomb eyecare auction
Bausch + Lomb was put up for sale after a planned separation from its parent company Bausch Health, formerly known as ...
Buy Rating Reaffirmed for Bausch Health on Prospective Bausch + Lomb Sale and Value Unlocking
Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...
The Motley Fool7d
Why Bausch + Lomb Rallied Today
It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch Health's lenders would apparently prefer a sale for cash. The stock is surging today on news the ...
AOL7d
Why Bausch + Lomb Rallied Today
Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...
Morningstar7d
Bausch + Lomb's stock soars 14% on report company is considering selling itself
The company (BLCO), which was carved out of parent Bausch Health Cos. Inc. (BHC) in 2022, is working with Goldman Sachs to explore a deal and expects to draw interest from private equity firms ...
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...